title: Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients.
abstract: BACKGROUND
  Increased risk of cardiovascular and cerebrovascular disease in liver transplant recipients results in particular from the side effects of calcineurin inhibitor-based immunosuppressive therapy. Several studies have demonstrated a more favourable outcome for patients receiving tacrolimus (TAC) as compared with ciclosporin (CS).
  
  
  OBJECTIVE
  To investigate the effects of conversion from CS to TAC on cardiovascular risk factors and renal function in liver transplant recipients.
  
  
  METHODS
  In a prospective study, all except two patients had chronic kidney disease stages 2-4 (n = 80), according to estimated glomerular filtration rate using the abbreviated Modification of Diet in Renal Disease equation.
  
  
  RESULTS
  Conversion was accompanied with a mean decrease of total cholesterol from 194.6 +/- 54.0 mg/dL to 175.8 +/- 44.2 mg/dL (P < 0.001), low density lipoprotein cholesterol from 106.7 +/- 39.2 mg/dL to 90.9 +/- 28.6 mg/dL (P < 0.001) and mean arterial blood pressure values from 102.2 +/- 13.2 mm Hg to 95.9 +/- 11.7 mm Hg (P < 0.001). Renal function remained stable. No cases of de novo diabetes mellitus were identified. The Framingham risk score was significantly reduced from 5.2 +/- 4.4 at baseline to 4.4 +/- 5.3 after 12 months (P = 0.006).
  
  
  CONCLUSIONS
  Conversion from CS to TAC has been shown to improve the cardiovascular risk profile and may retard further decline of renal function after liver transplantation.
authors.affiliation: Department of General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany. susanne.beckebaum@uni-due.de
authors.forename: S
authors.initials: S
authors.lastname: Beckebaum
authors.forename: C
authors.initials: C
authors.lastname: Klein
authors.forename: J
authors.initials: J
authors.lastname: Varghese
authors.forename: G C
authors.initials: GC
authors.lastname: Sotiropoulos
authors.forename: F
authors.initials: F
authors.lastname: Saner
authors.forename: K
authors.initials: K
authors.lastname: Schmitz
authors.forename: G
authors.initials: G
authors.lastname: Gerken
authors.forename: A
authors.initials: A
authors.lastname: Paul
authors.forename: V R
authors.initials: VR
authors.lastname: Cicinnati
mesh_terms: D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002908:Chronic Disease; D016572:Cyclosporine / Q000009:adverse effects; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control*; D007677:Kidney Function Tests; D008107:Liver Diseases / Q000150:complications / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus